# US 2014/0155609 A9 · Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155609 A9
- Document ID: US20140155609A9
- Status: Published application
- Kind: A9
- Application number: 13/989,407
- Filed: 2010-11-24
- Published: 2014-06-05
- Earliest claimed: 2010-11-24
- Assignees: Dong-A St Co., Ltd.
- Inventors: Miwon Son; Tae Ho Lee; Sang Zin Choi; Nam Joon Baek; Kang Ro Lee; Ki Hyun Kim; Soon Hoe Kim
- Web page: https://patentgrep.com/patent/US20140155609A9

## CPC

- C07D 221/18: Ring systems of four or more rings
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a novel quinoline derivative compound, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or a solvate thereof. The novel quinoline derivative compound, the optical isomer thereof, the pharmaceutically acceptable salt thereof, and the hydrate or the solvate thereof accelerates gastrointestinal movement, and thus can effectively prevent or treat gastrointestinal motility disorders.

## Claims

### Claim 1

A quinoline derivative compound represented by the following Chemical Formula 1, an optical isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:
wherein for Chemical Formula 1:
R1 to R4 are independently —H or methoxy; and
R5 is linear or branched alkyl of C1 to C4.

### Claim 2 (depends on 1)

The quinoline derivative compound of claim 1 represented by Chemical Formula 1, the optical isomer, the pharmaceutically acceptable salt, or the hydrate or solvate thereof, wherein the quinoline derivative compound represented by Chemical Formula 1 is a compound represented by the following Chemical Formula 2:
wherein * represents an asymmetric carbon atom.

### Claim 3 (depends on 1)

The quinoline derivative compound of claim 1 represented by Chemical Formula 1, the optical isomer, the pharmaceutically acceptable salt, or the hydrate or solvate thereof, wherein the quinoline derivative compound represented by Chemical Formula 1 is (S)-4-oxo-4-(1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydro-dibenzo[de,g]quinoline-6-yl)-butyric acid ethyl ester.

### Claim 4

A method for preparing a compound represented by the following Chemical Formula 1, an optical isomer thereof, a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof, comprising reacting a compound represented by the following Chemical Formula 3 or an optical isomer thereof with a compound represented by the following Chemical Formula 4 or an optical isomer thereof in presence of a base:
wherein for Chemical Formula 1, 3 and 4:
R1 to R4 are independently —H or methoxy;
R5 is linear or branched alkyl of C1 to C4;
X is Cl, Br or I; and
* represents an asymmetric carbon atom.

### Claim 5 (depends on 4)

The method of claim 4, wherein R1 to R4 are methoxy, R5 is ethyl, and X is Cl.

### Claim 6

A pharmaceutical composition for prevention or treatment of a gastrointestinal motility disorder, comprising a novel quinoline derivative compound represented by the following Chemical Formula 1, an optical isomer thereof, a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof:
wherein for Chemical Formula 1:
R1 to R4 are independently —H or methoxy; and
R5 is linear or branched alkyl of C1 to C4.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, wherein the compound represented by Chemical Formula 1 is (S)-4-oxo-4-(1,2,9,10-tetramethoxy-4,5,6a,7-tetrahydro-dibenzo[de,g]-quinoline-6-yl)-butyric acid ethyl ester.